Pfizer Inc. (FRA:PFE)
21.19
+0.34 (1.61%)
Oct 20, 2025, 9:55 PM CET
Pfizer Revenue
Pfizer had revenue of $14.65 billion USD in the quarter ending June 29, 2025, with 10.31% growth. This brings the company's revenue in the last twelve months to $63.83 billion, up 13.53% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63 billion with 6.84% growth.
Revenue (ttm)
$63.83B
Revenue Growth
+13.53%
P/S Ratio
2.19
Revenue / Employee
$788.06K
Employees
81,000
Market Cap
119.48B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bayer Aktiengesellschaft | 46.17B |
Siemens Healthineers AG | 23.38B |
Fresenius SE & Co. KGaA | 22.28B |
Merck KGaA | 21.22B |
Fresenius Medical Care AG | 19.52B |
Sartorius Aktiengesellschaft | 3.52B |
Redcare Pharmacy NV | 2.68B |
Fielmann Group AG | 2.40B |
Pfizer News
- 15 hours ago - Pfizer's (PFE) Crizotinib Shows Promise in Uveal Melanoma Trial - GuruFocus
- 16 hours ago - Pfizer (PFE): Promising Data from VERITAC-2 Trial on Breast Cancer Treatment - GuruFocus
- 18 hours ago - Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy - GlobeNewsWire
- 1 day ago - Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study - Nasdaq
- 1 day ago - Pfizer (PFE) Reports Positive PADCEV Trial Results at ESMO 2025 - GuruFocus
- 1 day ago - XTANDI Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Wallstreet:Online
- 1 day ago - XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer - Business Wire
- 1 day ago - Pfizer’s BRAFTOVI + MEKTOVI Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer - Wallstreet:Online